Cargando…

Prescribing Prevalence, Effectiveness, and Mental Health Safety of Smoking Cessation Medicines in Patients With Mental Disorders

OBJECTIVE: We conducted a prospective cohort study of the Clinical Practice Research Database to estimate rates of varenicline and nicotine replacement therapy (NRT) prescribing and the relative effects on smoking cessation, and mental health. METHODS: We used multivariable logistic regression, prop...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Gemma M J, Itani, Taha, Thomas, Kyla H, Rai, Dheeraj, Jones, Tim, Windmeijer, Frank, Martin, Richard M, Munafò, Marcus R, Davies, Neil M, Taylor, Amy E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073926/
https://www.ncbi.nlm.nih.gov/pubmed/31289809
http://dx.doi.org/10.1093/ntr/ntz072
_version_ 1783506722715860992
author Taylor, Gemma M J
Itani, Taha
Thomas, Kyla H
Rai, Dheeraj
Jones, Tim
Windmeijer, Frank
Martin, Richard M
Munafò, Marcus R
Davies, Neil M
Taylor, Amy E
author_facet Taylor, Gemma M J
Itani, Taha
Thomas, Kyla H
Rai, Dheeraj
Jones, Tim
Windmeijer, Frank
Martin, Richard M
Munafò, Marcus R
Davies, Neil M
Taylor, Amy E
author_sort Taylor, Gemma M J
collection PubMed
description OBJECTIVE: We conducted a prospective cohort study of the Clinical Practice Research Database to estimate rates of varenicline and nicotine replacement therapy (NRT) prescribing and the relative effects on smoking cessation, and mental health. METHODS: We used multivariable logistic regression, propensity score matched regression, and instrumental variable analysis. Exposure was varenicline or NRT prescription. Mental disorders were bipolar, depression, neurotic disorder, schizophrenia, or prescriptions of antidepressants, antipsychotics, hypnotics/anxiolytics, mood stabilizers. Outcomes were smoking cessation, and incidence of neurotic disorder, depression, prescription of antidepressants, or hypnotics/anxiolytics. Follow-ups were 3, 6, and 9 months, and at 1, 2, and 4 years. RESULTS: In all patients, NRT and varenicline prescribing declined during the study period. Seventy-eight thousand four hundred fifty-seven smokers with mental disorders aged ≥18 years were prescribed NRT (N = 59 340) or varenicline (N = 19 117) from September 1, 2006 to December 31, 2015. Compared with smokers without mental disorders, smokers with mental disorders had 31% (95% CI: 29% to 33%) lower odds of being prescribed varenicline relative to NRT, but had 19% (95% CI: 15% to 24%) greater odds of quitting at 2 years when prescribed varenicline relative to NRT. Overall, varenicline was associated with decreased or similar odds of worse mental health outcomes than NRT in patients both with and without mental disorders, although there was some variation when analyses were stratified by mental disorder subgroup. CONCLUSIONS: Smoking cessation medication prescribing may be declining in primary care. Varenicline was more effective than NRT for smoking cessation in patients with mental disorders and there is not clear consistent evidence that varenicline is adversely associated with poorer mental health outcomes. IMPLICATIONS: Patients with mental disorders were less likely to be prescribed varenicline than NRT. We triangulated results from three analytical techniques. We found that varenicline was more effective than NRT for smoking cessation in patients with mental disorders. Varenicline was generally associated with similar or decreased odds of poorer mental health outcomes (ie, improvements in mental health) when compared with NRT. We report these findings cautiously as our data are observational and are at risk of confounding.
format Online
Article
Text
id pubmed-7073926
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-70739262020-03-19 Prescribing Prevalence, Effectiveness, and Mental Health Safety of Smoking Cessation Medicines in Patients With Mental Disorders Taylor, Gemma M J Itani, Taha Thomas, Kyla H Rai, Dheeraj Jones, Tim Windmeijer, Frank Martin, Richard M Munafò, Marcus R Davies, Neil M Taylor, Amy E Nicotine Tob Res Original Investigations OBJECTIVE: We conducted a prospective cohort study of the Clinical Practice Research Database to estimate rates of varenicline and nicotine replacement therapy (NRT) prescribing and the relative effects on smoking cessation, and mental health. METHODS: We used multivariable logistic regression, propensity score matched regression, and instrumental variable analysis. Exposure was varenicline or NRT prescription. Mental disorders were bipolar, depression, neurotic disorder, schizophrenia, or prescriptions of antidepressants, antipsychotics, hypnotics/anxiolytics, mood stabilizers. Outcomes were smoking cessation, and incidence of neurotic disorder, depression, prescription of antidepressants, or hypnotics/anxiolytics. Follow-ups were 3, 6, and 9 months, and at 1, 2, and 4 years. RESULTS: In all patients, NRT and varenicline prescribing declined during the study period. Seventy-eight thousand four hundred fifty-seven smokers with mental disorders aged ≥18 years were prescribed NRT (N = 59 340) or varenicline (N = 19 117) from September 1, 2006 to December 31, 2015. Compared with smokers without mental disorders, smokers with mental disorders had 31% (95% CI: 29% to 33%) lower odds of being prescribed varenicline relative to NRT, but had 19% (95% CI: 15% to 24%) greater odds of quitting at 2 years when prescribed varenicline relative to NRT. Overall, varenicline was associated with decreased or similar odds of worse mental health outcomes than NRT in patients both with and without mental disorders, although there was some variation when analyses were stratified by mental disorder subgroup. CONCLUSIONS: Smoking cessation medication prescribing may be declining in primary care. Varenicline was more effective than NRT for smoking cessation in patients with mental disorders and there is not clear consistent evidence that varenicline is adversely associated with poorer mental health outcomes. IMPLICATIONS: Patients with mental disorders were less likely to be prescribed varenicline than NRT. We triangulated results from three analytical techniques. We found that varenicline was more effective than NRT for smoking cessation in patients with mental disorders. Varenicline was generally associated with similar or decreased odds of poorer mental health outcomes (ie, improvements in mental health) when compared with NRT. We report these findings cautiously as our data are observational and are at risk of confounding. Oxford University Press 2019-07-10 /pmc/articles/PMC7073926/ /pubmed/31289809 http://dx.doi.org/10.1093/ntr/ntz072 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Investigations
Taylor, Gemma M J
Itani, Taha
Thomas, Kyla H
Rai, Dheeraj
Jones, Tim
Windmeijer, Frank
Martin, Richard M
Munafò, Marcus R
Davies, Neil M
Taylor, Amy E
Prescribing Prevalence, Effectiveness, and Mental Health Safety of Smoking Cessation Medicines in Patients With Mental Disorders
title Prescribing Prevalence, Effectiveness, and Mental Health Safety of Smoking Cessation Medicines in Patients With Mental Disorders
title_full Prescribing Prevalence, Effectiveness, and Mental Health Safety of Smoking Cessation Medicines in Patients With Mental Disorders
title_fullStr Prescribing Prevalence, Effectiveness, and Mental Health Safety of Smoking Cessation Medicines in Patients With Mental Disorders
title_full_unstemmed Prescribing Prevalence, Effectiveness, and Mental Health Safety of Smoking Cessation Medicines in Patients With Mental Disorders
title_short Prescribing Prevalence, Effectiveness, and Mental Health Safety of Smoking Cessation Medicines in Patients With Mental Disorders
title_sort prescribing prevalence, effectiveness, and mental health safety of smoking cessation medicines in patients with mental disorders
topic Original Investigations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073926/
https://www.ncbi.nlm.nih.gov/pubmed/31289809
http://dx.doi.org/10.1093/ntr/ntz072
work_keys_str_mv AT taylorgemmamj prescribingprevalenceeffectivenessandmentalhealthsafetyofsmokingcessationmedicinesinpatientswithmentaldisorders
AT itanitaha prescribingprevalenceeffectivenessandmentalhealthsafetyofsmokingcessationmedicinesinpatientswithmentaldisorders
AT thomaskylah prescribingprevalenceeffectivenessandmentalhealthsafetyofsmokingcessationmedicinesinpatientswithmentaldisorders
AT raidheeraj prescribingprevalenceeffectivenessandmentalhealthsafetyofsmokingcessationmedicinesinpatientswithmentaldisorders
AT jonestim prescribingprevalenceeffectivenessandmentalhealthsafetyofsmokingcessationmedicinesinpatientswithmentaldisorders
AT windmeijerfrank prescribingprevalenceeffectivenessandmentalhealthsafetyofsmokingcessationmedicinesinpatientswithmentaldisorders
AT martinrichardm prescribingprevalenceeffectivenessandmentalhealthsafetyofsmokingcessationmedicinesinpatientswithmentaldisorders
AT munafomarcusr prescribingprevalenceeffectivenessandmentalhealthsafetyofsmokingcessationmedicinesinpatientswithmentaldisorders
AT daviesneilm prescribingprevalenceeffectivenessandmentalhealthsafetyofsmokingcessationmedicinesinpatientswithmentaldisorders
AT tayloramye prescribingprevalenceeffectivenessandmentalhealthsafetyofsmokingcessationmedicinesinpatientswithmentaldisorders